This study provided comprehensive real‐world evidence regarding clinical efficacy of chemo‐based combination therapies for advanced NSCLC with EGFR ex20ins alterations in the first‐line setting in China. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.